Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q37310407

about

Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea Management of the adverse effects of lenalidomide in multiple myeloma.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Spotlight on lenalidomide in relapsed or refractory multiple myeloma.Immunomodulatory drugs in multiple myeloma.Kidney dysfunction during lenalidomide treatment for AL amyloidosis.Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure.Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.Pulmonary toxicities from targeted therapies: a review.Latest advances and current challenges in the treatment of multiple myeloma.SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.Review of therapeutic options and the management of patients with myelodysplastic syndromes.Perspectives in the treatment of multiple myeloma.An old drug with a new future: bendamustine in multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.NQO1 C609T Polymorphism is Associated with Coronary Artery Disease in a Gender-Dependent Manner.Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

P2860

Q26823292-90D2AE84-FED4-4B39-85D6-12333BAF5BE5 Q26992002-3C9D58AD-F61D-41B6-A70B-F7B86ABA611D Q33394632-7433170D-FBD1-43CA-A048-DF3B8CB1E425 Q33404007-02EC7DC1-AE45-45DE-AD55-F2073FAFFCDB Q33414647-8CA9C9B0-71A1-4B55-B332-A243A2CBBB10 Q33441702-2DC46394-4219-4351-83A9-3AB0AF431CE1 Q34028642-28602D57-0408-430C-8528-B38B9684B0ED Q34325722-5C02CEAB-F0D8-4A89-BCA6-5BEFC4D87454 Q35025410-DECDD9BA-7D5E-418B-871F-E1D96AC72B5A Q36934144-3D60F395-70B8-4F1D-A2A0-57520460246A Q37609434-B35C69A6-C3BD-41E7-86B7-48291CCD9FF3 Q37835695-CC4735E9-1ACE-4879-ACBD-0EFF5D93FE5D Q37858523-E8BE76B1-C7D6-4504-AB5C-7D710E0A1933 Q37955066-EFDE566E-FE6D-45D3-B07D-FED101ADE026 Q37986287-6B6E5C2F-35AB-4F01-AF08-22B40EC42784 Q38000078-E1F7FA0E-461E-40D3-A903-9A12A44C1C0B Q38037600-F39104DF-62BB-4A0D-BCDF-F7BAC8C2916D Q38065298-A26E0ABD-CE72-42F5-A2A2-75A1ACE22377 Q38095121-78D6DC6E-11DF-44DF-B260-7BF7CBE1758E Q38108391-CC278FF6-7B66-4BF7-AC87-1ED1C93D9CFE Q38139989-5D9C4BD4-0F8F-4D2B-867F-924C8426B0BA Q38545607-A2668E0C-919D-4F20-93AB-86E568EEE605 Q38783950-4FE04155-2A9B-463B-AC9C-42EBC472E685 Q40186008-F88E7D0D-336A-46BA-BB06-84F175FBBB82 Q42867447-A262C720-B822-4182-817F-AC6098B90AC5 Q47096268-53FF1CE2-5153-418A-ACEB-CF18FC65E5BF Q50543689-F44414C9-BB61-4A5F-A839-E57680A9D130 Q57904195-B88E9304-5FB0-4372-BA0A-464C66668A81

P2860

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q37310407

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Expanded safety experience wit ...... r refractory multiple myeloma.

@en

Expanded safety experience wit ...... r refractory multiple myeloma.

@nl

type

label

Expanded safety experience wit ...... r refractory multiple myeloma.

@en

Expanded safety experience wit ...... r refractory multiple myeloma.

@nl

prefLabel

Expanded safety experience wit ...... r refractory multiple myeloma.

@en

Expanded safety experience wit ...... r refractory multiple myeloma.

@nl

P1433

Q37310407-9D4687FF-0A01-4E5A-AA67-78C38120816E

P1476

Q37310407-2ADA83EE-83F8-4324-8A2A-6347A0233E83

P2093

Q37310407-09D5C931-B4F8-4E7C-939F-79DFEAF59997

Q37310407-1CC71DA8-6372-4BB8-AAF8-A3B672FAA0D0

Q37310407-3C5EC948-2626-4501-A267-1C2ED3A78082

Q37310407-5EA2FCB5-A501-4DD2-B182-8CA3D52331A4

Q37310407-610B4608-3CD5-4660-8E62-E863265BDD73

Q37310407-70B87820-49EC-4B52-A8CA-C25510A804C0

Q37310407-8306D47D-0D33-4534-931B-813D8DD0BBA2

Q37310407-A9E9BF64-BE73-4980-BD14-F3094A520837

Q37310407-A9FCD0DD-E443-4971-8B28-3DB6DDD6C08C

Q37310407-B48B2347-B036-4E24-8D5E-0102AAB43EAD

P2860

Q37310407-0E1D3603-A85B-40DB-9002-72C8A1DA88E0

Q37310407-2190394E-3839-469A-9693-90AFB7442168

Q37310407-33DCAE3C-A299-42EE-90F2-81B51BEC09A8

Q37310407-378582BD-D5D8-4AD4-B62A-EE28403BE19C

Q37310407-39FC4FBD-979F-4539-85A1-42C7FB1D08AF

Q37310407-60ABB8F3-2584-4DF0-B91D-93E7AC77C549

Q37310407-62F1037C-760F-49A9-8A1C-59CCB6380C79

Q37310407-67793F74-B682-448D-B60E-E4FA9C8F5010

Q37310407-689337FE-6CFA-4DE5-9901-E9ECCCFAB3A7

Q37310407-6DB3D76D-1645-43B5-8551-F456E42FCD1C

P304

Q37310407-C5F8850E-DDAE-4769-AD7F-714F64D7651C

P31

Q37310407-DF4737FA-834B-4E78-8F7E-D0907B47BF73

P356

Q37310407-11427894-8B06-49F6-A0EA-9F7FAD89DDB9

P407

Q37310407-B3CFBDCC-8D14-434B-8977-5459FBFA9634

P433

Q37310407-321AAA7B-9DB9-4EFE-9F63-A4B2B3656C97

P478

Q37310407-3A71FB35-F11F-4DA4-AB0C-2575BE2B4FC3

P50

Q37310407-16122A1C-5B17-4743-91E4-17D5295AEBF6

Q37310407-FE8A2174-AF17-4F09-8379-B74F5981951A

P577

Q37310407-D78A14C9-B3C7-4931-8235-E93C17AC59AF

P5875

Q37310407-A0CB4B60-2784-454D-B49A-CDD47BA50857

P698

Q37310407-14DBEA4B-5752-4262-9F56-A20A6A00B5AD

P921

Q37310407-70A38CB7-F3AC-484F-B470-92A486F5B678

P932

Q37310407-9060E918-D105-4A47-9D5E-1AC45176C37B

P356

J.1365-2141.2009.07728.X

P1433

British Journal of Haematology

P1476

Expanded safety experience wit ...... r refractory multiple myeloma.

@en

P2093

Christine Chen

http://www.w3.org/2001/XMLSchema#string

David Siegel

http://www.w3.org/2001/XMLSchema#string

Dennis Pietronigro

http://www.w3.org/2001/XMLSchema#string

Donna E Reece

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Jeffrey Matous

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Melissa Alsina

http://www.w3.org/2001/XMLSchema#string

Nizar J Bahlis

http://www.w3.org/2001/XMLSchema#string

Rafat Abonour

http://www.w3.org/2001/XMLSchema#string

P2860

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Antitumor activity of thalidomide in refractory multiple myeloma.

Multiple myeloma.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

P304

164-170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2009.07728.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

146

http://www.w3.org/2001/XMLSchema#string

P50

Paul G Richardson

Ruben Niesvizky

P577

2009-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26309899

http://www.w3.org/2001/XMLSchema#string

P698

19545290

http://www.w3.org/2001/XMLSchema#string

P921

P932

2728892

http://www.w3.org/2001/XMLSchema#string